: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2015 Financial Results Utica, New York

CONMED Corporation Announces

Fourth Quarter and Fiscal Year 2015 Financial Results

Utica, New York, January 27,

2016 --- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the fourth quarter and fiscal year ended December

Fourth Quarter 2015 Highlights

Fiscal Year 2015 Highlights

"We are pleased with our accomplishments

during fiscal 2015, particularly the early signs that our turnaround efforts are starting to gain traction. Despite continued headwinds

in our export markets, we reversed the trend of top-line deterioration experienced in 2014 and exited 2015 with two consecutive

quarters of constant currency revenue growth. In addition, gross margin improvement in the second half of the year and lower operating

expenses as a result of cost saving initiatives are positive trends we intend to build on entering 2016," commented Curt

R. Hartman, CONMED's President and Chief Executive Officer. "Based on progress made in 2015, and with new commercial

leadership in place, we are confident in our ability to deliver continued improvement in operational performance in 2016. Our team

is committed to capitalizing on the SurgiQuest acquisition, to investing in innovation, and to further enhancing CONMED's

growth opportunities domestically and internationally."

For the quarter ended December

31, 2015, domestic sales, which represented 51.1% of total revenue, decreased 0.9%, as growth in Orthopedics was offset by declines

in General Surgery and Visualization. International sales, which represented 48.9% of total revenue, declined 3.2% compared to

the fourth quarter of 2014 on a reported basis. Foreign currency exchange rates, including the effects of the FX hedging program,

had a negative impact of $3.9 million on fourth quarter sales. In constant currency, international sales increased 2.1% versus

the prior-year period.

For the fiscal year ended December

31, 2015, domestic sales, which represented 50.3% of total revenue, increased 0.5% and were driven by increases in capital equipment

sales across all businesses. International sales, which represented 49.7% of total revenue, declined 6.0% compared to the same

period a year ago on a reported basis. Foreign currency exchange rates, including the effects of the FX hedging program, had a

negative impact of $22.9 million on fiscal year sales. In constant currency, international sales increased 0.1% versus the prior-year

For the quarter ended December

31, 2015, reported net earnings totaled $7.9 million, compared to reported net earnings of $11.3 million a year ago. Reported diluted

net earnings per share were $0.28 in the quarter, compared to $0.41 in the prior-year period. Reported net earnings include restructuring

and business acquisition costs in 2015 and restructuring costs in 2014. The effect of each of these items on reported net earnings

appears in the reconciliation of GAAP to non-GAAP measures below.

Excluding the impact of the items

described above, adjusted net earnings of $14.5 million decreased 1.8% year over year and adjusted diluted net earnings per share

of $0.52 decreased 1.9% year over year. The decline in adjusted net earnings was largely attributable to the negative impact of

foreign currency and a slightly higher tax rate, partially offset by improved gross margin during the quarter.

For the fiscal year ended December

31, 2015, reported net earnings totaled $30.5 million, compared to reported net earnings of $32.2 million in the prior year. Reported

diluted net earnings per share were $1.09 compared to $1.16 in the prior-year period. Excluding the impact of the special items

provided in the reconciliation of GAAP to non-GAAP measures below, adjusted net earnings of $46.7 million decreased 12.5% year

over year, and adjusted diluted net earnings per share of $1.68 decreased 12.5% from the prior year.

The Company forecasts 2016 sales

to be in the range of $760 to $770 million compared to $719 million in 2015. This revenue forecast includes constant currency organic

sales growth of 1% to 3%, sales related to the SurgiQuest acquisition of $55 to $60 million and the negative impact of foreign

exchange of $21 to $23 million (based on January 25, 2016 exchange rates and existing hedges).

Beginning in 2016, the Company

will exclude amortization of intangible assets from its adjusted earnings per share. Adjusted diluted cash earnings per share for 2015

would have been $1.98 if amortization of intangible assets were excluded.

Based on 2016 revenue of $760 to

$770 million, the Company forecasts 2016 adjusted diluted cash earnings per share to be in the range of $1.85 to $1.95.

The adjusted diluted cash earnings

per share estimates for 2016 exclude the cost of special items including acquisition costs and restructuring costs which are estimated

to be in the range of $18 to $20 million, net of tax, and amortization of intangible assets estimated to be in the range of $14

to $16 million, net of tax.

Supplemental Financial Disclosures

In conjunction with this earnings

press release, CONMED has prepared supplemental financial disclosures which are available on the home page of the "Investors

- Financial Reports" section of the Company's web site at www.conmed.com.

The Company's management

will host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2015 results.

To participate in the conference

call, dial 877-573-5235 (domestic) or 503-406-4448 (international) and enter the passcode 16884173.

This conference call will also

be webcast and can be accessed from the Investors section of CONMED's web site at www.conmed.com. The webcast replay of

the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also

be available from 7:30 p.m. ET on Wednesday, January 27, 2016 until 11:59 p.m. ET on Wednesday, February 3, 2016. To hear this

recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 16884173.

About CONMED Corporation

CONMED is a medical technology company

that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons

and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

The Company distributes its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 17

countries and international sales constitute approximately 50% of the Company's total sales. Headquartered in Utica, New

York, the Company employs approximately 3,500 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release contains forward-looking

statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements

are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's

performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which

could cause actual results, performance or trends to differ materially from those expressed in the forward-looking statements herein

or in previous disclosures. In addition to general industry and economic conditions, factors that could cause actual results to

differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to,

the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended

December 31, 2014 and Form 8-K filed January 4, 2016.

Supplemental Information - Reconciliation of GAAP

to Non-GAAP Financial Measures

The Company supplements the reporting

of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain

non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding

specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted effective income tax rate; adjusted

net earnings, adjusted diluted net earnings per share (EPS) and adjusted cash EPS. The Company believes that these non-GAAP measures

provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects

for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described

above are important indicators of our operations because they exclude items that may not be indicative of, or are unrelated to,

our core operating results and provide a baseline for analyzing trends in the Company's underlying businesses. Further, the

presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's

cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future

business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial

To measure percentage sales growth